Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Translational Neurodegeneration
Published in: Translational Neurodegeneration 1/2018

Open Access 01-12-2018 | Review

The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms

Authors: Bob G. Schultz, Denise K. Patten, Daniel J. Berlau

Published in: Translational Neurodegeneration | Issue 1/2018

Login to get access

Abstract

Nearly 30% of adults 40 years and older in the United States are on a statin. Their widespread use heightens the importance of careful consideration of their varied effects on the body. Although randomized controlled trials have not confirmed cognitive impairing effects with statins, continuing evidence suggests statins have the ability to cause reversible cognitive impairment in some patients. Paradoxically, statins have also been shown to decrease the risk of dementia, Alzheimer’s disease, and improve cognitive impairment in some cases. However, randomized controlled trials have similarly failed to find the beneficial effect. Supporting evidence for both claims is compelling whereas known limitations of the clinical trials may explain the lack of findings. This narrative review aims to explain why there is still controversy and how both effects can, and may, be possible. The mechanisms that have been hypothesized for each effect are seemingly independent from one another and may explain the contradicting results. Being mindful of the complex effects of statins, health care providers need to be able to identify patients who are at risk for or already experiencing cognitive impairment from statin use while also identifying those who could potentially decrease their risk of dementia with statins.
Literature
1.
CDC. NCHS. Underlying Cause of Death 1999-2013 on CDC WONDER Online Database. Underlying Cause Death 1999-2013 CDC WONDER Online Database. 2015.
2.
Karalis DG. Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease. Mayo Clin Proc. 2009;84:345–52.CrossRefPubMedPubMedCentral
3.
4.
5.
Tuohy CV, Dodson J. Statins for Primary Prevention in Older Adults. Am J Cardiol. 2015;
6.
Ott BR, Daiello LA, Dahabreh IJ, Springate BA, Bixby K, Murali M, et al. Do Statins Impair Cognition? A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Gen Intern Med. 2015;30:348–58.CrossRefPubMedPubMedCentral
7.
8.
Hammer GP, du Prel J-B, Blettner M. Avoiding bias in observational studies: part 8 in a series of articles on evaluation of scientific publications. Dtsch Arztebl Int. 2009;106:664–8.PubMedPubMedCentral
9.
Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet. 2002;360:1623–30.CrossRefPubMed
10.
Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006;97:33A–41A.CrossRefPubMed
11.
Heart protection Study Collaborative group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.CrossRef
12.
Mcguinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2016;
13.
Posvar EL, Radulovic LL, Cilla DD, Whitfield LR, Sedman AJ. Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. J Clin Pharmacol. 1996;36:728–31.CrossRefPubMed
14.
Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-Associated Memory Loss: Analysis of 60 Case Reports and Review of the Literature. Pharmacotherapy. 2003;23:871–80.CrossRefPubMed
15.
Muldoon MF, Barger SD, Ryan CM, Flory JD, Lehoczky JP, Matthews KA, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med. 2000;108:538–46.CrossRefPubMed
16.
Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med. 2004;117:823–9.CrossRefPubMed
17.
Evans MA, Golomb BA. Statin-Associated Adverse Cognitive Effects: Survey Results from 171 Patients. Pharmacotherapy. 2009;29:800–11.CrossRefPubMed
18.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.CrossRefPubMed
19.
Sahebzamani FM, Munro CL, Marroquin OC, Diamond DM, Keller E, et al. Examination of the FDA Warning for Statins and Cognitive Dysfunction. Aust J Pharm. 2014;2:141.
20.
Cham S, Koslik HJ, Golomb BA. Mood, Personality, and Behavior Changes During Treatment with Statins: A Case Series. Drug Saf Case Rep. 2016;3:1.CrossRefPubMed
21.
22.
Richardson K, Schoen M, French B, Umscheid CA, Mitchell MD, Arnold SE, et al. Statins and cognitive function: a systematic review. Ann Intern Med. 2013;159:688–97.CrossRefPubMed
23.
Benito-León J, Louis ED, Vega S, Bermejo-Pareja F. Statins and cognitive functioning in the elderly: A population-based study. J Alzheimers Dis. 2010;21:95–102.CrossRefPubMed
24.
Lilly SM, Mortensen EM, Frei CR, Pugh MJ, Mansi IA. Comparison of the risk of psychological and cognitive disorders between persistent and nonpersistent statin users. Am J Cardiol. 2014;114:1035–9.CrossRefPubMed
25.
Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS. Statins and cognition: A systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc. 2013;88:1213–21.CrossRefPubMed
26.
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation. 2014;129:S1–45.CrossRefPubMed
27.
Bernstein AB, Remsburg RE. Estimated Prevalence of People with Cognitive Impairment: Results from Nationally Representative Community and Institutional Surveys. Gerontologist. 2007;47:350–4.CrossRefPubMed
28.
Saheki A, Terasaki T, Tamai I, Tsuji A. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res. 1994;11:305–11.CrossRefPubMed
29.
Golomb BA, Criqui MH, White HL, Dimsdale JE. The UCSD Statin Study: A randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. Control Clin Trials. 2004;25:178–202.CrossRefPubMedPubMedCentral
30.
Nissen S, Nicholls S, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis. JAMA. 2006;295:1556–65.CrossRefPubMed
31.
Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009:453–63.
32.
Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439–43.CrossRefPubMed
33.
Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356:1627–31.CrossRefPubMed
34.
Shah NP, Swiger KJ, Martin SS. Impact on Cognitive Function—Are All Statins the Same? Curr Atheroscler Rep. 2015:1–7.
35.
Wong WB, Lin VW, Boudreau D, Devine EB. Statins in the prevention of dementia and Alzheimer’s disease: A meta-analysis of observational studies and an assessment of confounding. Pharmacoepidemiol Drug Saf. 2013;22:345–58.CrossRefPubMed
36.
Chatterjee S, Krishnamoorthy P, Ranjan P, Roy A, Chakraborty A, Sabharwal MS, et al. Statins and cognitive function: an updated review. Curr Cardiol Rep. 2015:4.
37.
Simons M, Schwärzler F, Lütjohann D, Von Bergmann K, Beyreuther K, Dichgans J, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer’s disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol. 2002;52:346–50.CrossRefPubMed
38.
Li G, Shofer JB, Rhew IC, Kukull WA, Peskind ER, McCormick W, et al. Age-varying association between statin use and incident Alzheimer’s disease. J Am Geriatr Soc. 2010;58:1311–7.CrossRefPubMedPubMedCentral
39.
Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59:223–7.CrossRefPubMed
40.
Green RC, McNagny SE, Jayakumar P, Cupples LA, Benke K, Farrer LA. Statin use and the risk of Alzheimer’s disease: The MIRAGE Study. Alzheimers Dement. 2006;2:96–103.CrossRefPubMed
41.
Pfefferkorn JA, Song Y, Sun KL, Miller SR, Trivedi BK, Choi C, et al. Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors. Bioorganic. Med Chem Lett. 2007;17:4538–44.CrossRef
42.
Zissimopoulos JM, Barthold D, Brinton RD, Joyce G. Sex and race differences in the association between statin use and the incidence of Alzheimer disease. JAMA Neurol. 2017;74:225–32.CrossRefPubMedPubMedCentral
43.
Geifman N, Brinton RD, Kennedy RE, Schneider LS, Butte AJ. Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease. Alzheimers Res Ther. 2017;9:10.CrossRefPubMedPubMedCentral
44.
Sparks D, Kryscio R, Sabbagh M, Connor D, Sparks L, Liebsack C. Reduced risk of incidenct AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res. 2008;5:416–21.CrossRefPubMed
45.
46.
Power M, Rawlings A, Sharrett A, Bandeen-Roche K, Coresh J, Ballantyne C, et al. Association of midlife lipids with 20-year cognitive change: A cohort study. Alzheimers Dement. 2017;S1552-5260:33691–9.
47.
Anstey KJ, Ashby-Mitchell K, Peters R. Updating the Evidence on the Association between Serum Cholesterol and Risk of Late-Life Dementia: Review and Meta-Analysis. J Alzheimers Dis. 2017;56:215–28.CrossRefPubMedPubMedCentral
48.
Schilling S, Tzourio C, Soumaré A, Kaffashian S, Dartigues JF, Ancelin ML, et al. Differential associations of plasma lipids with incident dementia and dementia subtypes in the 3C Study: A longitudinal, population-based prospective cohort study. PLoS Med. 2017;14
49.
Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology. 1993;43:2412.CrossRefPubMed
50.
Sinyavskaya L, Gauthier S, Renoux C, Dell’Aniello S, Suissa S, Brassard P. Comparative effect of statins on the risk of incident Alzheimer disease. Neurology. 2018;90:e179–87.CrossRefPubMed
51.
Houx PJ, Shepherd J, Blauw G-J, Murphy MB, Ford I, Bollen EL, et al. Testing cognitive function in elderly populations: the PROSPER study. PROspective Study of Pravastatin in the Elderly at Risk. J Neurol Neurosurg Psychiatry. 2002;73:385–9.CrossRefPubMedPubMedCentral
52.
Appleton JP, Scutt P, Sprigg N, Bath PM. Hypercholesterolaemia and vascular dementia. Clin Sci. 2017;131:1561–78.CrossRefPubMed
53.
Orth M, Bellosta S. Cholesterol: Its regulation and role in central nervous system disorders. Cholesterol. 2012;
54.
55.
56.
Canestaro WJ, Austin MA, Thummel KE. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review. Genet Med. 2014;16:810–9.CrossRefPubMedPubMedCentral
57.
Kim MC, Ahn Y, Jang SY, Cho KH, Hwang SH, Lee MG, et al. Comparison of Clinical Outcomes of Hydrophilic and Lipophilic Statins in Patients with Acute Myocardial Infarction. Korean J Intern Med. 2011;26:294.CrossRefPubMedPubMedCentral
58.
Hamelin B. Hydrophilicity/ lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998;19:26–37.CrossRefPubMed
59.
Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundam Clin Pharmacol. 2005:117–25.
60.
Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84:413–28.CrossRefPubMed
61.
White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol. 2002;42:963–70.CrossRefPubMed
62.
63.
64.
Golomb BA, Evans MA. Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8:373–418.CrossRefPubMedPubMedCentral
65.
De Vivo DC, DiMauro S. Mitochondrial defects of brain and muscle. Biol Neonate. 1990;58(Suppl 1):54–69.CrossRefPubMed
66.
Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423.CrossRefPubMedPubMedCentral
67.
Ostrowski SM, Wilkinson BL, Golde TE, Landreth G. Statins reduce amyloid-?? Production through inhibition of protein isoprenylation. J Biol Chem. 2007;282:26832–44.CrossRefPubMed
68.
Leduc V, De Beaumont L, Theroux L, Dea D, Aisen P, Petersen RC, et al. HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer’s disease in a three cohorts study. Mol Psychiatry. 2015;20:867–73.CrossRefPubMed
69.
Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, et al. A Cholesterol-Lowering Drug Reduces β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer’s Disease. Neurobiol Dis. 2001;8:890–9.CrossRefPubMed
70.
Zhang Y, Fan Y, Wang M, Wang D, Li X. Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer’s disease. Clin Interv Aging. 2013;8:103–10.PubMedPubMedCentral
71.
72.
Wood WG, Mΰller WE, Eckert GP. Statins and Neuroprotection: Basic Pharmacology Needed. Mol Neurobiol. 2014;50:214–20.CrossRefPubMed
73.
Alzheimer Association. 2016 Alzheimer’s Disease Facts and Figures. Alzheimers Dement. 2016;12:1–80.CrossRef
74.
Van Aelst L, D’Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 1997;11:2295–322.CrossRefPubMed
Metadata
Title
The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms
Authors
Bob G. Schultz
Denise K. Patten
Daniel J. Berlau
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Translational Neurodegeneration / Issue 1/2018
Electronic ISSN: 2047-9158
DOI
https://doi.org/10.1186/s40035-018-0110-3

Other articles of this Issue 1/2018

Translational Neurodegeneration 1/2018 Go to the issue

Research

Cognitive characteristics in Chinese non-demented PD patients based on gender difference

Research

Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome

Review

Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer’s disease –conformist, nonconformist, and realistic prospects for AD pathogenesis

Review

Hydrogen sulfide, nitric oxide, and neurodegenerative disorders

Research

AGE-induced neuronal cell death is enhanced in G2019S LRRK2 mutation with increased RAGE expression

Correction

Correction to: Alterations of brain local functional connectivity in amnestic mild cognitive impairment